Rinvoq ER 30 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DR26FHY9B
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,748
Award facts
- Contract value 100% obligated
- $20,747.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,747.76 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on November 5, 2025, with an ultimate completion date of November 6, 2025. This firm fixed-price delivery order was not set aside for small business, reflecting the contractor's competitive capability in federal pharmaceutical procurement. The award was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates delivery capability across multiple therapeutic domains, from specialty medications to generic drugs. As a child contract action under the SPE2DX IDC, this delivery order exemplifies the operational flexibility of the DLA's pharmaceutical prime vendor model, which supports the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. RINVOQ ER (upadacitinib extended-release) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in supplying specialized pharmaceutical products to military medical facilities.
Quick answers
Who was awarded contract SPE2DR26FHY9B?
SPE2DR26FHY9B was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DR26FHY9B worth?
The government has obligated $20,748 on SPE2DR26FHY9B.
Is contract SPE2DR26FHY9B an order under another contract?
Yes. SPE2DR26FHY9B is a delivery order under SPE2DR25D1106, an indefinite delivery contract.
Was contract SPE2DR26FHY9B competed?
The extent of competition for SPE2DR26FHY9B was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award